IP Library Granted Patent US 8,357,780
Granted Patent B2
US 8,357,780 · App. 12/663,498 · Granted Jan 22, 2013

Polypeptides, antibody variable domains and antagonists methods for

Inventors: Laurent Jespers (Cambridgeshire, GB); Malgorzata Pupecka (Cambridgeshire, GB); Ian Tomlinson (Stevenage, GB); Carolyn Enever (Cambridgeshire, GB)
Assignee: Domantis Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,357,780
App. No.
12/663,498
Granted
Jan 22, 2013
Kind
B2
Abstract

The invention relates to anti-IL-1R1 polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for as therapeutics and/or prophylactics that are likely to encounter proteases when administered to a patient, for example for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating inflammatory disease, such as arthritis or COPD.

Claims (12)

1. An isolated immunoglobulin single variable domain comprising an amino acid sequence with at least 98% identity to the amino acid sequence shown in SEQ ID NO: 238; wherein the immunoglobulin single variable domain binds Interleukin-1 Receptor Type 1.

2. The isolated immunoglobulin single variable domain of claim 1 comprising a serine at Kabat position 22, a serine at Kabat position 49, a serine at Kabat position 83 and a tyrosine at Kabat position 94.

3. The isolated immunoglobulin single variable domain of claim 1 comprising the amino acid sequence shown in SEQ ID NO: 238.

4. The isolated immunoglobulin single variable domain of claim 3 encoded by the nucleic acid sequence shown in SEQ ID NO: 50.

5. An isolated polypeptide comprising an immunoglobulin single variable domain that comprises an amino acid sequence with at least 98% identity to the amino acid sequence shown in SEQ ID NO: 238; wherein the immunoglobulin single variable domain binds Interleukin-1 Receptor Type 1.

6. The isolated polypeptide of claim 5 wherein the immunoglobulin single variable domain comprises a serine at Kabat position 22, a serine at Kabat position 49, a serine at Kabat position 83 and a tyrosine at Kabat position 94.

7. An isolated polypeptide comprising an immunoglobulin single variable domain that comprises the amino acid sequence shown in SEQ ID NO: 238; wherein the immunoglobulin single variable domain binds Interleukin-1 Receptor Type 1.

8. An isolated polypeptide comprising an immunoglobulin single variable domain that comprises the amino acid sequence shown in SEQ ID NO: 238; wherein the immunoglobulin single variable domain binds Interleukin-1 Receptor Type 1 and that is encoded by the nucleic acid sequence shown in SEQ ID NO: 50.

9. An isolated composition comprising the isolated immunoglobulin single variable domain of claim 1 and a pharmaceutically acceptable carrier.

10. An isolated composition comprising the isolated immunoglobulin single variable domain of claim 3 and a pharmaceutically acceptable carrier.

11. An isolated composition comprising the isolated polypeptide of claim 5 and a pharmaceutically acceptable carrier.

12. An isolated composition comprising the isolated polypeptide of claim 7 and a pharmaceutically acceptable carrier.

Assignments (2)
CHANGE OF ADDRESS Recorded Oct 1, 2025
From: DOMANTIS LIMITED
To: DOMANTIS LIMITED
Reel/Frame 072987/0472 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 20, 2011
From: JESPERS, LAURENT; PUPECKA, MALGORZATA; TOMLINSON, IAN; ENEVER, CAROLYN
To: DOMANTIS LIMITED
Reel/Frame 026623/0787 →
Priority Claims (1)
GB 0724331.4 · Dec 13, 2007 · national
Continuity (2)
Provisional Application 60933632 · Jun 6, 2007
Related Publication 20100260763A1 · Oct 14, 2010